In relation to the inflammatory activity of MS, to define potential biomarkers of the various MS disease forms, levels of C3, C4, and C9 were mostly investigated, providing convincing evidence of the role of complement compounds in MS disease development. The gene discussed is C9; the disease is myeloid sarcoma.